MedTrace Logo

PRospective Multiple Myeloma Impact Study

NCT02911571 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2026-04-28

No results posted yet for this study

Summary

This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.

Conditions

Interventions

DEVICE

MMprofiler SKY92 gene signature

MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 "high-risk" gene signature to aid in the determination of the Multiple Myeloma patient's prognosis

Sponsors & Collaborators

  • Medex15

    collaborator INDUSTRY

  • SkylineDx

    lead INDUSTRY

Principal Investigators

  • Saad Usmani, MD · Charlotte Mecklenburg Hospital Authority, Carolinas HealthCare System

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-27
Primary Completion
2022-04-18
Completion
2026-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02911571 on ClinicalTrials.gov